Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.80 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.55 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrapentylammonium SCHEMBL31391250 | 0.93 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrahexylammonium SCHEMBL31391249 | 0.90 | SLC22A1 (0.81) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL9221599 | 0.90 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL106567 | 0.90 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5724808 | 0.90 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL22384 | 0.89 | SLC22A1 (1.00) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2007037 | 0.89 | SLC22A1 (1.00) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL71525 | 0.89 | SLC22A1 (1.00) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL6690901 | 0.87 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL104673 | 0.87 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189765-B2 | Process for the preparation of 17β-hydroxy-des-A-androst-9,10-en-5-one | INDUSTRIALE CHIMICA S.R.L. (IT) | 2019-01-29 | — | — | US | claimed |
| US-20180339956-A1 | PROCESS FOR THE PREPARATION OF 17BETA-HYDROXY-DES-A-ANDROST-9,10-EN-5-ONE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2018-11-29 | — | — | US | claimed |
| WO-2017072719-A1 | PROCESS FOR THE PREPARATION OF 17BETA-HYDROXY-DES-A-ANDROST-9,10-EN-5-ONE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2017-05-04 | — | — | WO | claimed |
| WO-2010058235-A1 | METHOD FOR THE PREPARATION OF OXYCAROTENOIDS | INNOVA ANDINA S.A. (PE) | 2010-05-27 | — | — | WO | claimed |
| EP-1840659-A2 | Composition for cleaning microelectronic substrates containing halogen oxygen acids and derivatives thereof | Mallinckrodt Baker, Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| EP-0480039-B1 | COMPOSITE MEMBRANE | TORAY INDUSTRIES (JP) | 2000-09-06 | — | — | EP | claimed |
| EP-0417287-B1 | POROUS MEMBRANE AND PROCESS FOR ITS MANUFACTURE | TORAY INDUSTRIES (JP) | 1994-06-08 | — | — | EP | claimed |
| US-5259950-A | Active layer with polyphenylenesulfide sulfone porous coating | TORAY INDUSTRIES, INC. (JP) | 1993-11-09 | — | — | US | claimed |
| US-5112487-A | Ultrafiltration, durability, polythioether copolymer | TORAY INDUSTRIES, INC. (JP) | 1992-05-12 | — | — | US | claimed |
| EP-0480039-A1 | COMPOSITE MEMBRANE | TORAY INDUSTRIES, INC. (JP) | 1992-04-15 | — | — | EP | claimed |
| EP-0417287-A1 | POROUS MEMBRANE AND PROCESS FOR ITS MANUFACTURE | TORAY INDUSTRIES, INC. (JP) | 1991-03-20 | — | — | EP | claimed |
| US-12628593-B2 | Method for treating transition metal semiconductor, and reducing agent-containing treatment liquid for transition metal oxide | TOKUYAMA CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12509632-B2 | Treatment liquid for semiconductors and method for producing same | TOKUYAMA CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| CN-120060857-A | Treatment liquid for ruthenium semiconductor and method for producing same | 株式会社德山 | 2025-05-30 | — | — | CN | disclosed |
| US-12247299-B2 | Treatment liquid for semiconductor with ruthenium and method of producing the same | TOKUYAMA CORPORATION (JP) | 2025-03-11 | — | — | US | disclosed |
| EP-0417287-B1 | POROUS MEMBRANE AND PROCESS FOR ITS MANUFACTURE | TORAY INDUSTRIES (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5259950-A | Active layer with polyphenylenesulfide sulfone porous coating | TORAY INDUSTRIES, INC. (JP) | 1993-11-09 | — | — | US | disclosed |
| US-5112487-A | Ultrafiltration, durability, polythioether copolymer | TORAY INDUSTRIES, INC. (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0480039-A1 | COMPOSITE MEMBRANE | TORAY INDUSTRIES, INC. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0417287-A1 | POROUS MEMBRANE AND PROCESS FOR ITS MANUFACTURE | TORAY INDUSTRIES, INC. (JP) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339956-A1 | PROCESS FOR THE PREPARATION OF 17BETA-HYDROXY-DES-A-ANDROST-9,10-EN-5-ONE | HSD17B11, CYP19A1, CYP17A1 | SLC22A1 3456/4885SLC22A2 3997/4885ALDH1A1 391/4885 |
| US-12628593-B2 | Method for treating transition metal semiconductor, and reducing agent-containing treatment liquid for transition metal oxide | CA6, CA3, SOST | SLC22A1 3804/4885SLC22A2 3789/4885ALDH1A1 3279/4885 |
| US-10189765-B2 | Process for the preparation of 17β-hydroxy-des-A-androst-9,10-en-5-one | CYP19A1, HSD17B11, CYP17A1 | SLC22A1 3370/4885SLC22A2 3897/4885ALDH1A1 341/4885 |
| US-12509632-B2 | Treatment liquid for semiconductors and method for producing same | GRIN2D, WIZ, EED | SLC22A1 4852/4885SLC22A2 4832/4885ALDH1A1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.